In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss ...

WEIGHT loss jabs such as Ozempic, Mounjaro and Wegovy have offered a lifeline to those with diabetes and obesity. But not everyone who takes the GLP-1 receptor agonists benefits equally, warn ...